SCHEMBL5138038

SCHEMBL5138038

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
CASR P41180 2/20 0.41
CRHR1 P34998 2/20 0.39
TSHR P16473 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP3A4 P08684 3/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
PDE4B Q07343 2/20 0.38
HSD11B1 P28845 1/20 0.37
BCHE P06276 1/20 0.36
HDAC1 Q13547 1/20 0.36
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648044 0.97 CASR (0.44) C5AR1CASRCRHR1TSHRKDM4E
SCHEMBL5135742 0.95 C5AR1 (0.40) C5AR1CASRCRHR1TSHRKDM4E
SCHEMBL5138030 0.93 CASR (0.44) C5AR1CASRCRHR1TSHRKDM4E
SCHEMBL5134621 0.93 CASR (0.43) C5AR1CASRCRHR1TSHRKDM4E
SCHEMBL5075018 0.92 CRHR1 (0.40) C5AR1CASRCRHR1TSHRKDM4E
SCHEMBL649659 0.91 CASR (0.46) C5AR1CASRTSHRKDM4EALDH1A1
SCHEMBL5137962 0.91 C5AR1 (0.44) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135279 0.90 GAA (0.46) C5AR1CASRTSHRKDM4EALDH1A1
SCHEMBL5136301 0.90 CASR (0.45) C5AR1CASRTSHRKDM4EALDH1A1
SCHEMBL5136887 0.90 C5AR1 (0.43) C5AR1CRHR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed